Introduction {#Sec1}
============

Chronic heart failure (CHF) is a complex syndrome characterized by increased activity of the sympathetic nervous system,[@CR1],[@CR2] increased NT-proBNP levels, and increased pro-inflammatory cytokines in plasma and myocardial tissue.[@CR3],[@CR4] Inflammation plays an important role in the pathogenesis and progression of many forms of heart failure (HF). With progression of CHF, the plasma levels of pro-inflammatory cytokines increase. In addition, cardiac sympathetic hyperactivity is associated with progression of CHF.[@CR5] However, there is only limited information on the relation between the sympathetic nervous activity and the inflammatory status in CHF patients.

Cardiac sympathetic activity can non-invasively be assessed with cardiac ^123^I-*meta*-iodobenzylguanidine (^123^I-*m*IBG). *m*IBG is a norepinephrine (NE) analog that shares the same presynaptic uptake, storage, and release mechanisms as NE. Radiolabeling of *m*IBG with ^123^I allows imaging with gamma cameras.[@CR6] The heart-to-mediastinum (H/M) ratio reflects presynaptic myocardial uptake of ^123^I-*m*IBG. The early H/M ratio reflects predominantly the integrity of sympathetic nerve terminals (i.e., number of functioning nerve terminals and intact uptake-1 mechanism). The late H/M ratio offers predominantly information about neuronal function resulting from uptake, storage, and release. The myocardial ^123^I-*m*IBG washout (WO) reflects predominantly neuronal integrity of sympathetic tone/adrenergic drive.[@CR7] The late H/M ratio and ^123^I-*m*IBG WO have been shown to be of clinical value, especially for the assessment of prognosis, in many cardiac diseases.[@CR8] ^--^ [@CR12] Decreased late H/M ratio and increased ^123^I-*m*IBG WO are associated with poor outcome in subjects with CHF.[@CR5],[@CR11]

The aim of this study was to identify the relationship between severity of HF (i.e., NT-proBNP and LVEF), cardiac sympathetic activity assessed with ^123^I-*m*IBG scintigraphy, and measures of inflammation in patients with stable CHF. In addition, we evaluated the prognostic value of these inflammatory markers and myocardial ^123^I-*m*IBG-derived parameters (i.e., late H/M ratio and ^123^I-*m*IBG WO).

Material and Methods {#Sec2}
====================

Subjects {#Sec3}
--------

Patients with stable CHF (New York Heart Association (NYHA) class II to III), who were referred for ^123^I-*m*IBG scintigraphy in their work-up for primary ICD implantation between 2010 and 2015 to the department of Nuclear Medicine of the Academic Medical Center in Amsterdam, were enrolled. The inclusion criteria were as follows: stable heart failure (i.e., no myocardial infarction, hospitalization, or progression of heart failure) at least 3 months before inclusion and treatment with optimal medical therapy according to the European HF guidelines including beta-blockers and angiotensin-converting-enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB) and if necessary loop diuretics.[@CR13] Exclusion for participation was pregnancy or intolerance for iodine. All subjects provided written informed consent. The study was approved by the local institutional review board and conducted according to the principles of the International Conference on Harmonization--Good Clinical Practice.

^123^I-*m*IBG Scintigraphy Acquisition and Analysis {#Sec4}
---------------------------------------------------

All patients continued their HF medication prior to ^123^I-*m*IBG scintigraphy. To block uptake of free ^123^I by the thyroid gland, subjects were pretreated with 250 mg oral potassium iodide 30 minutes before intravenous (IV) injection of 185 MBq ^123^I-*m*IBG (GE Healthcare, Eindhoven, the Netherlands). Fifteen minutes (early acquisition) and 4 hours (late acquisition) after administration of ^123^I-*m*IBG, 10-minutes planar images were acquired with the subjects in supine position using a gamma camera equipped with a medium-energy (ME) collimator.

All planar ^123^I-*m*IBG images were analyzed by one experienced observer (D.O.V.) blinded to patient data. Heart-to-mediastinum (H/M) ratios were calculated from the ^123^I-*m*IBG images using a region-of-interest (ROI) over the heart and the upper part of the mediastinum (Figure [1](#Fig1){ref-type="fig"}).[@CR14] The H/M ratio was calculated by dividing the mean count density in the cardiac ROI by the mean count density in the mediastinal ROI.[@CR14] The ^123^I-*m*IBG WO was calculated as follows:$$\documentclass[12pt]{minimal}
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                \begin{document}$$ {\text{ WO }} = \left\{ {\frac{{ ( {\text{early H/M ratio) }} - ({\text{late H/M ratio)}}}}{\text{early H/M ratio}}} \right\}\,\; \times \; 100$$\end{document}$$ Figure 1Example of processing procedure for planar ^123^I-*m*IBG images. The positioning of the mediastinal ROI was standardized in relation to the lung apex, the lower boundary of the upper mediastinum, and the midline between the lungs

Markers of Inflammation {#Sec5}
-----------------------

Before administration of 185 MBq ^123^I-*m*IBG, 2 × 4.0 mL of venous blood was collected into ethylenediaminetetraacetic acid (EDTA)-containing tubes. Immediately after collection of the required blood volume, one EDTA tube was analyzed for CRP and NT-proBNP by standard procedures. The second EDTA tube was mixed with the sampled blood and immediately cooled on ice. Within 30 min of collection, the tubes were centrifuged at 1700 g for 10 minutes. The plasma was transferred to cryovals and stored in upright position at -70 °C till analysis. All samples were analyzed at the end of the study for IL-1β, IL-6, IL-8, IL-10, IL-12p40, TNF-α, sE-selectin, MPO, PAI-1, tPA, TNFR1 and TNFR2, and INF α and β by luminex. Samples were measured with ProCarta reagents (eBioscience) following the supplier's protocol and read on a Bioplex 200 (BioRad).

Clinical Follow-up and Event Adjudication. {#Sec6}
------------------------------------------

Follow-up was based on telephone interviews (D.O.V.) and medical records. All subjects received standard clinical care and were followed up until (1) the death of a subject was confirmed or (2) the trial was terminated. The Clinical Adjudication Committee reviewed data from case report forms and source documents to confirm the occurrence of CEs, specifically (1) HF progression: increase in symptomatic status from NYHA functional class II to III or IV, or increase from NYHA class III to class IV; (2) potentially life-threatening arrhythmic event, including documented episode of spontaneous sustained (30 seconds) ventricular tachyarrhythmia, resuscitated cardiac arrest, or appropriate ICD discharge (antitachycardia pacing or defibrillation); or (3) cardiac death (further classified as due to HF progression, sudden cardiac death \[SCD\]).

Statistical Analysis {#Sec7}
--------------------

All continuous variables are expressed as mean ± standard deviation. After demonstrating a normal distribution of variables, between-group comparisons were performed using independent-sample *t* tests. Non-detectable levels of biomarkers were treated as zeroes for the analysis. Continuous data were compared using analysis of variance (ANOVA). The association between ^123^I-*m*IBG outcomes and biomarkers was assessed using Pearson's correlation coefficient (2-tailed). Multivariate linear regression analysis was performed to determine independent predictors of ^123^I-*m*IBG parameters. The overall goodness-of-fit for each model was expressed as the adjusted R^2^. The F-test was used to assess whether a model explained a significant proportion of the variability. A *p* value \< 0.05 was considered to indicate a statistical significance. Univariate and multivariate Cox proportional hazards regression analysis was used to assess independent predictors of cardiac events. ROC analysis was used to determine the optimal cut-off value (i.e., highest product of sensitivity and specificity) for predictors of CEs. Statistical analyses were performed with SPSS, release 22.0 for Windows (SPSS Inc., Chicago, IL, USA 2003).

Results {#Sec8}
=======

In total, 252 patients with CHF were screened for enrollment. However, the majority of the subjects did not met the inclusion criteria (at least 3 months stable heart failure), already participate in other studies, or refused to give informed consent. Baseline patient characteristics including ^123^I-*m*IBG-derived parameters are presented in Table [1](#Tab1){ref-type="table"}. The study population comprised 55 stable CHF patients (43 male and 12 female) with a mean age of 66.3 ± 8.0 years. Forty-one (75%) patients were in NYHA class II and 14 (25%) we in NYHA class III. The mean LVEF was 22.4 ± 6.3% and 60% of the patients had ischemic heart disease. The mean early H/M ratio was 2.12 ± 0.39, the late H/M ratio was 1.84 ± 0.40, and the mean ^123^I-*m*IBG WO was 13.0 ± 10.9. Most of the plasma levels of IL-1β, IL-6, IL-8, IL-10, TNFR1, IFN-α, and IFN-β were below the detection limit. Table [2](#Tab2){ref-type="table"} shows only biomarkers with levels above lower limit of detection in all patients.Table 1Baseline clinical characteristics of CHF patientsAll (*n* = 55)Cardiac event (*n* = 13)No cardiac event (*n* = 42)*p* valueAge (years)66.3 ± 8.066.4±7.066.2±8.40.118Male (%)43 (78)10 (77)33 (79)0.809Etiology heart failure0.79 Ischemic (%)33 (60)8 (62)25 (60) Non-ischemic (%)22 (40)5 (38)17 (40)Blood pressure Systolic (mmHg)125 ± 17126 ± 14125 ± 190.223 Diastolic (mmHg)76 ± 1077±875±110.148LVEF (%)22.4 ± 6.323.9 ± 6.622.1 ± 6.20.491NYHA0.051Class II (%)41 (75)8 (62)33 (79)Class III (%)14 (25)5 (38)9 (21)Medication Betablockers (%)43 (78)9 (69)34 (81)0.118 ACE-I/ARB s(%)50 (91)13 (100)37 (88)0.004 MRAs (%)18 (33)5 (38)13 (31)0.560 Loop diuretics (%)38 (69)10 (77)28 (67)0.122 Statines (%)38 (69)9 (69)29 (69)0.980 Aspirin (%)32 (58)6 (46)26 (62)0.448^123^I-*m*IBG parameters Early H/M ratio2.12 ± 0.392.00 ± 0.282.16 ± 0.420.140 Late H/M ratio1.84 ± 0.401.66 ± 0.281.90 ± 0.420.137 ^123^I-*m*IBG WO13.0 ± 10.919.8 ± 10.611.8 ± 10.80.897 Table 2Biomarkers of CHF patientsAll (*n* = 55)Cardiac event (*n* = 13)No cardiac event (*n* = 42)*p* valueCRP (mg/L)5.44 ± 11.079.4 ± 20.34.2 ± 5.90.001TNF-α (pg/mL)6.00 ± 2.415.56 ± 1.416.12 ± 2.650.483sE-selectin (ng/mL)26.33 ± 10.6728.91 ± 10.8325.54 ± 10.620.800IL-12p40 (pg/mL)7.51 ± 5.589.68 ± 6.816.83 ± 5.040.154MPO (ng/mL)72.60 ± 56.4452.05 ± 32.3178.96 ± 60.950.018PAI-1 (ng/mL)8.50 ± 1.698.50 ± 2.048.51 ± 1.600.355tPA (ng/mL)1.56 ± 0.681.73 ± 0.831.51 ± 0.640.294TNFR2 (pg/mL)174 ± 57191 ± 50168 ± 580.602NT-proBNP (ng/L)1974 ± 30263280 ± 54021570 ± 16750.000

Association Between ^123^I-*m*IBG and Markers of Inflammation {#Sec9}
-------------------------------------------------------------

The LVEF, NYHA functional class, NT-proBNP, CRP, TNFα, TNFR2, sE-selectin, IL12p40, MPO, PAI-1, and tPA were used as explanatory variables of late H/M ratio and ^123^I-*m*IBG WO. Late H/M ratio was significantly associated with LVEF (*R* = 0.342, *p* = 0.011) and NT-proBNP (*R* = −0.272, *p* = 0.045). ^123^I-*m*IBG WO was also significantly associated with LVEF (*R* = −0.286, *p* = 0.034), NYHA (*R* = 0.281, *p* = 0.038), and NT-proBNP (*R* = 0.325, *p* = 0.015). Multivariate regression analysis using both biomarkers and clinical parameters (i.e., LVEF, NYHA functional class) showed LVEF as the only independent predictor of late H/M ratio (adjusted *R* ^2^ = 0.100, *p* = 0.011). NT-proBNP was the only independent parameter associated with ^123^I-*m*IBG WO (adjusted *R* ^2^ = 0.090, *p* = 0.015) (Table [3](#Tab3){ref-type="table"}).Table 3Multivariate regression analysis to determine independent predictors for late H/M ratio (upper panel) and ^123^I-*m*IBG WO (lower panel)VariabelsCoefficient *b*Standard error *bp* valueConstant1.3510.193LVEF0.0220.0080.011Goodness-to-fit of the modelAdjusted *R* ^2^*p* value0.1000.011VariabelsCoefficient *b*Standard error *bp* valueConstant10.6671.678NT-proBNP0.0010.0000.015Goodness-to-fit of the modelAdjusted *R* ^2^*p* value0.0900.015

Predictors of cardiac events {#Sec10}
----------------------------

None of the patients were lost during a median follow-up of 34 months (2--58 months). Thirteen patients (24%) experienced a first CE: progression of HF (*n* = 4), arrhythmic event with appropriate ICD discharge (*n* = 4), and cardiac death (*n* = 5; four subjects due to sudden cardiac death (SCD) and one due to progression of HF). In addition, one patient had a non-cardiac death. There was a significant difference in plasma levels of NT-proBNP, CRP, and MPO between patients with and without CEs (Table [2](#Tab2){ref-type="table"}). However, there was no significant difference in late H/M ratio and ^123^I-*m*IBG WO between both groups. Univariate Cox regression analysis showed that the risk of a CE was associated with CRP, NT-proBNP, MPO, and late H/M ratio (Table [4](#Tab4){ref-type="table"}). Multivariate Cox regression analysis showed that CRP, MPO, IL-12p40, and NT-proBNP were independent predictors of a CE. CRP, MPO, IL12p40, and NT-proBNP did not show any mutual relationship with each other (data not shown). Figure [2](#Fig2){ref-type="fig"} shows cumulative event curves for the late H/M ratio and CRP. ROC analysis showed that the optimal cut-off values for the late H/M ratio and CRP were 1.68 and 1.85 mg/L, respectively. These cut-off values resulted in a moderate discriminative power: AUC for late H/M ratio 0.69 and for CRP 0.64, respectively).Figure 2Examples of cumulative event curves for different parameters. **A** Comparing CHF patients with late H/M ratio \<1.68 versus \>1.68 (*p* = 0.019). **B** Comparing CHF patients with CRP \< 1.85 mg/L versus CRP \> 1.85 mg/L (*p* = 0.032) Table 4Univariate and multivariate Cox regression analysis for cardiac eventsVariableUnivariateMultivariateHR (95% CI)*p* valueHR (95% CI)*X* ^2^ change*p* valueCRP (mg/L)1.047 (1.013--1.081)0.0001.050 (1.012--1.089)4.7670.009NT-proBNP (ng/L)1.141 (1.011--1.288)0.0231.177 (1.013--1.367)3.3300.034IL-12p40 (pg/mL)1.072 (0.980--1.173)0.1231.158 (1.045--1.283)5.9420.005MPO (ng/mL)0.985 (0.971--0.999)0.0300.981 (0.965--0.995)5.2530.014LVEF (%)1.033 (0.949--1.123)0.452NYHA2.096 (0.683--6.426)0.186TNF-α (pg/mL)0.787 (0.508--1.219)0.302sE-selectin (ng/mL)1.009 (0.958--1.063)0.730PAI-1 (ng/mL)0.892 (0.626--1.271)0.528tPA (ng/mL)1.059 (0.468--2.396)0.890TNFR2 (pg/mL)1.002 (0.992--1.011)0.743Early H/M ratio0.323 (0.065--1.600)0.166Late H/M ratio0.182 (0.035--0.946)0.042^123^I-*m*IBG WO1.045 (0.987--1.106)0.136

Discussion {#Sec11}
==========

The findings of this study show that in this specific, optimally treated and stable CHF population, general markers of inflammation were not associated with increased cardiac sympathetic activity assessed with ^123^I-*m*IBG. In addition, the cardiac sympathetic activity was associated with severity of heart failure (i.e., NT-proBNP and LVEF). In line with the lack of association between myocardial ^123^I-*m*IBG parameters and markers of inflammation, both were related to the prognosis of this specific CHF population.

Irrespective of the etiology of CHF, pro-inflammatory cytokines are implicated in the progression of CHF.[@CR4],[@CR15],[@CR16] In CHF patients, increased levels of TNF-α are associated with impaired LV function and consequently increased mortality.[@CR17],[@CR18] Although the exact mechanism of TNF-α in relation to CHF remains to be elucidated, it has been reported that TNF-α induces β-adrenergic receptor (βAR) desensitization.[@CR19] This phenomenon identifies a cross-talk between TNF-α and βAR function that at least in part contributes to a potential further reduction in cardiac contractility in CHF. In addition, increased levels of IL-6 have been reported in CHF patients and are correlated to plasma levels of NE (*R* = 0.839, *p* \< 0.0001).[@CR20] In our study, plasma levels of IL-1β, IL-6, IL-10, IFN-α, IFN-β, and TNFR1 were below the detection limit. We consider it unlikely that our procedure failed to detect these cytokines as we took great care to process the blood samples quickly and limit activation. In addition, the earlier spike experiments for these cytokines yielded good recoveries and the internal standards were correct, A possible explanation for these undetectable levels could be the treatment with statins (hydroxymethylglutaryl-CoA reductase inhibitors), aspirin, ACE-Is, ARBs, mineralocorticoid receptor antagonists (MRAs), and beta-blockers. Statins have pleiotropic benefits independent of cholesterol levels including anti-inflammatory effects and it has been suggested that statins might reduce the production of TNF-α, IL-1, and IL-6.[@CR21] ^--^ [@CR23] In addition, aspirin, ACE-Is/ARBs, MRAs, and beta-blockers have been shown to decrease plasma levels of cytokines.[@CR24] Consequently, the use of these drugs could have influenced the plasma levels of cytokines in our population. In addition, these findings may suggest that our stable CHF patients were optimally treated.

In line with others, we showed increased cardiac sympathetic activity (i.e., decreased late H/M ratio and increased ^123^I-*m*IBG WO) in a stable CHF population.[@CR11],[@CR25],[@CR26] However, in contrast to previous studies with IDCM,[@CR27],[@CR28] our study did not show a significant correlation between the most important markers of inflammation (i.e., TNF-α, IL-1β, and IL-6) and cardiac sympathetic activity. IL-1β and IL-6 levels were below the lower limit of quantification, whereas TNF-α was detectable, but did not show a correlation. In conclusion, in this population of stable, optimally treated CHF, markers of inflammation were subordinate to the more frequently used markers of prognosis in CHF (i.e., NT-proBNP, LVEF, NYHA class) in relation to sympathetic activity.

LVEF and NT-proBNP were moderately, but significantly, related to late H/M ratio. In addition, LVEF, NT-proBNP, and NYHA class were moderately related to ^123^I-*m*IBG WO. Recently, it has been shown that BNP modulates autonomic nervous function by inhibiting cardiac sympathetic activity in CHF.[@CR29] As in CHF, prolonged increased cardiac sympathetic activity has a detrimental effect on the contractility of the myocardium, this influences the LVEF. This is in line with the found negative association between LVEF and ^123^I-*m*IBG WO.

Predictor of Cardiac Events {#Sec12}
---------------------------

Increased cardiac sympathetic activity occurs early in the CHF disease process. Initially, βAR stimulation by the increased NE levels helps to compensate for impaired myocardial function, but long-term NE excess has detrimental effects on myocardial structure and gives rise to a downregulation of post-synaptic βARs.[@CR30] This downregulation leads to left ventricle remodeling and poor prognosis. In our study, decreased late H/M ratio was associated with CEs (Figure [2](#Fig2){ref-type="fig"}A). This is line with two large meta-analyses and a large prospective multicenter trial.[@CR11],[@CR25],[@CR26] However, in our study, not late H/M ratio, but CRP, MPO, IL12p40, and NT-proBNP were the only independent predictors of CEs.

CRP is regarded a non-specific marker for acute inflammation. Several studies have examined CRP levels in coronary heart disease and have demonstrated its prognostic value.[@CR31],[@CR32] Interestingly, in our study, CRP levels were significantly higher in patients with an event compared to whose without CEs (Figure [2](#Fig2){ref-type="fig"}B). Similar results were reported in IDCM patients.[@CR33] The past decade high-sensitive (hs)CRP has been introduced and is commonly used for cardiovascular risk stratification. Increased hsCRP is associated with increased risk for cardiovascular disease and mortality.[@CR34]

MPO, an enzyme derived from neutrophilic granulocytes reflects inflammation and plaque destabilization. In addition to a possible candidate biomarker to predict future adverse events in patients with acute coronary syndromes (ASC) and myocardial infarction,[@CR35],[@CR36] MPO has been associated with the severity of CHF.[@CR4] In our study, the levels of MPO were elevated. Interestingly, activation of neutrophils leads to the release of preformed IL-8 and MPO. As we found no IL-8 in conjunction with MPO, we consider it unlikely that MPO was generated during processing of blood samples.[@CR37] In contrast to previous studies, [@CR35],[@CR36] we found a negative association between these elevated levels of MPO and CEs, suggesting a protective mechanism of MPO. However, due to the relatively limited sample size, this extraordinary finding should be interpreted with great care.

IL-12p40 is elevated in an early stage of atherosclerosis both at the mRNA and protein level.[@CR38] Elevated levels of IL-12p40 have also been reported in patients with coronary artery disease (CAD).[@CR39],[@CR40] Interestingly, in a murine atherosclerosis study, aspirin reduced the levels of IL-12p40, suggesting the involvement of IL-12p40 on vascular inflammation.[@CR41] Our study showed a prognostic value of IL-12p40 in a stable CHF population. This association is most likely explained by the high percentage (i.e., 60%) of CAD in our CHF population.

NT-proBNP is a widely used powerful predictor of clinical outcome and a better marker for efficacy of drug treatment in patients with HF than other biomarkers or clinical parameters. Its clinical use has been endorsed in clinical practice guideline.[@CR13] NT-proBNP was an independent predictor of CEs, in line with previous results showing almost exponentially raising risk with increasing levels of NT-proBNP.[@CR42]

Our study has several limitations. The major limitation of the study is the relative small number of patients included. This may have resulted in a limited statistical power. Therefore, the results of the study should be regarded as insightful but preliminary and larger studies are necessary to confirm our findings. Second, the study population was heterogeneous including ischemic and non-ischemic heart disease. Although markers of inflammation were elevated in both groups, it is conceivable that elevation of these markers is more pronounced in the presence of atherosclerosis (i.e., ischemia). Third, the event rate was relatively low in this stable heart failure population, resulting in non-significant result for the individual endpoints. Therefore, a combination of the individual endpoints into a single endpoint was chosen. Finally, treatment with statins, aspirin, ACE-I or ARBs, MRAs, and beta-blockers may have influenced cytokine production. However, treatment of CHF with these drugs is followed according to the international HF guidelines. Therefore, our results are an accurate reflection of this specific stable CHF population.

In conclusion, this study demonstrated that some markers of inflammation were undetectable most likely reflecting adequate medical treatment in clinically stable and optimally treated CHF patients. However, there is no association between detectable general markers of inflammation and cardiac sympathetic activity in this stable CHF population. This was corroborated by the fact that both markers of inflammation and cardiac sympathetic activity were prognostic indicators of CEs.

New Knowledge Gained {#Sec100}
====================

The results of this study support the notion that inflammation and cardiac sympathetic activity are both important markers reflecting the multifactorial aspects of heart failure progression.
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